(R,S)-6-((4-chlorophenyl)(methylamino)(4-methylpyridin-3-yl)methyl)-4-(3-ethynylphenyl)-1-methylquinolin-2(1H)-one | 1189778-86-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: (R,S)-6-((4-chlorophenyl)(methylamino)(4-methylpyridin-3-yl)methyl)-4-(3-ethynylphenyl)-1-methylquinolin-2(1H)-one
• 英文别名: 6-[(4-Chlorophenyl)-(methylamino)-(4-methylpyridin-3-yl)methyl]-4-(3-ethynylphenyl)-1-methylquinolin-2-one；6-[(4-chlorophenyl)-(methylamino)-(4-methylpyridin-3-yl)methyl]-4-(3-ethynylphenyl)-1-methylquinolin-2-one
• CAS: 1189778-86-6
• 化学式: C₃₂H₂₆ClN₃O
• 分子量: 504.031
• InChiKey: HNPSKENMJCHDRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-[chloro-(4-chlorophenyl)-(4-methylpyridin-3-yl)methyl]-4-(3-ethynylphenyl)-1-methylquinolin-2-one 、 甲胺 以 四氢呋喃 、 甲醇 为溶剂， 生成 (R,S)-6-((4-chlorophenyl)(methylamino)(4-methylpyridin-3-yl)methyl)-4-(3-ethynylphenyl)-1-methylquinolin-2(1H)-one
  参考文献：
  名称：

  QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS

  摘要：

  提供了新型喹诺酮法尼西基转移酶抑制剂。这些新化合物在治疗或预防突触核蛋白病（如帕金森病、弥漫性莱维小体病、多系统萎缩和脑铁浓度紊乱疾病，包括泛酰辅酶A激酶相关的神经退行性疾病（例如PANK1）或其他神经退行性/神经系统疾病方面具有用处。提供的化合物还可用于治疗癌症等增生性疾病，以及治疗认知障碍、抑郁症和焦虑等神经系统疾病。治疗包括向受试者施用一种创新的法尼西基转移酶抑制剂化合物的治疗有效剂量。

  公开号：

  US20090253655A1

文献信息

• US8232402B2
  申请人：——

  公开号：US8232402B2

  公开（公告）日：2012-07-31
• [EN] QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS<br/>[FR] INHIBITEURS DE QUINOLINONE FARNÉSYL TRANSFÉRASE POUR LE TRAITEMENT DE SYNUCLÉINOPATHIES ET D'AUTRES INDICATIONS
  申请人：LINK MEDICINE CORP

  公开号：WO2009151683A2

  公开（公告）日：2009-12-17

  Novel quinolinone farnesyl transferase inhibitors are provided. These new compounds are useful in the treatment or prevention of synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease, multiple system atrophy, and disorders of brain iron concentration including pantothenate kinase-associated neurodegeneration (e.g., PANKl), or other neurodegenerative/neuro logical diseases. Provided compounds are also useful in the treatment of proliferative diseases such as cancer, and in the treatment of neurological diseases, such as cognitive impairment, depression, and anxiety. The treatment including administering to a subject a therapeutically effective amount of an inventive farnesyl transferase inhibitor compound.